Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI.


Journal

JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978

Informations de publication

Date de publication:
05 2019
Historique:
received: 13 11 2017
revised: 21 02 2018
accepted: 22 02 2018
pubmed: 24 4 2018
medline: 19 3 2020
entrez: 23 4 2018
Statut: ppublish

Résumé

This study aimed to compare the value of the index of microcirculatory resistance (IMR) and microvascular obstruction (MVO) measured by cardiac magnetic resonance (CMR) in patients treated for and recovering from ST-segment elevation myocardial infarction. IMR can identify patients with microvascular dysfunction acutely after primary percutaneous coronary intervention (pPCI), and a threshold of >40 has been shown to be associated with an adverse clinical outcome. Similarly, MVO is recognized as an adverse feature in patients with ST-segment elevation myocardial infarction. Even though both IMR and MVO reflect coronary microvascular status, the interaction between these 2 parameters is uncertain. A total of 110 patients treated with pPCI were included, and IMR was measured immediately at completion of pPCI. Infarct size (IS) as a percentage of left ventricular mass was quantified at 48 h (38.4 ± 12.0 h) and 6 months (194.0 ± 20.0 days) using CMR. MVO was identified and quantified at 48 h by CMR. Overall, a discordance between IMR and MVO was observed in 36.7% of cases, with 31 patients having MVO and IMR ≤40. Compared with patients with MVO and IMR ≤40, patients with both MVO and IMR >40 had an 11.9-fold increased risk of final IS >25% at 6 months (p = 0.001). Patients with MVO and IMR ≤40 had a significantly smaller IS at 6 months (p = 0.001), with significant regression in IS over time (34.4% [interquartile range (IQR): 27.3% to 41.0%] vs. 22.3% [IQR: 16.0% to 30.0%]; p = 0.001). Discordant prognostic information was obtained from IMR and MVO in nearly one-third of cases; however, IMR can be helpful in grading the degree and severity of MVO.

Sections du résumé

OBJECTIVES
This study aimed to compare the value of the index of microcirculatory resistance (IMR) and microvascular obstruction (MVO) measured by cardiac magnetic resonance (CMR) in patients treated for and recovering from ST-segment elevation myocardial infarction.
BACKGROUND
IMR can identify patients with microvascular dysfunction acutely after primary percutaneous coronary intervention (pPCI), and a threshold of >40 has been shown to be associated with an adverse clinical outcome. Similarly, MVO is recognized as an adverse feature in patients with ST-segment elevation myocardial infarction. Even though both IMR and MVO reflect coronary microvascular status, the interaction between these 2 parameters is uncertain.
METHODS
A total of 110 patients treated with pPCI were included, and IMR was measured immediately at completion of pPCI. Infarct size (IS) as a percentage of left ventricular mass was quantified at 48 h (38.4 ± 12.0 h) and 6 months (194.0 ± 20.0 days) using CMR. MVO was identified and quantified at 48 h by CMR.
RESULTS
Overall, a discordance between IMR and MVO was observed in 36.7% of cases, with 31 patients having MVO and IMR ≤40. Compared with patients with MVO and IMR ≤40, patients with both MVO and IMR >40 had an 11.9-fold increased risk of final IS >25% at 6 months (p = 0.001). Patients with MVO and IMR ≤40 had a significantly smaller IS at 6 months (p = 0.001), with significant regression in IS over time (34.4% [interquartile range (IQR): 27.3% to 41.0%] vs. 22.3% [IQR: 16.0% to 30.0%]; p = 0.001).
CONCLUSIONS
Discordant prognostic information was obtained from IMR and MVO in nearly one-third of cases; however, IMR can be helpful in grading the degree and severity of MVO.

Identifiants

pubmed: 29680355
pii: S1936-878X(18)30217-1
doi: 10.1016/j.jcmg.2018.02.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

837-848

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Auteurs

Giovanni Luigi De Maria (GL)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom; Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Mohammad Alkhalil (M)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Mathias Wolfrum (M)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Gregor Fahrni (G)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Alessandra Borlotti (A)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom; Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, Oxford, United Kingdom.

Lisa Gaughran (L)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Sam Dawkins (S)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Jeremy P Langrish (JP)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Andrew J Lucking (AJ)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Robin P Choudhury (RP)

Division of Cardiovascular Medicine, British Heart Foundation Centre of Research Excellence, University of Oxford, Oxford, United Kingdom; Department of Cardiology, Policlinico A. Gemelli, Università Cattolica del Sacro Cuore, Rome, Italy.

Italo Porto (I)

Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Filippo Crea (F)

Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Erica Dall'Armellina (E)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom; Acute Vascular Imaging Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.

Keith M Channon (KM)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Rajesh K Kharbanda (RK)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom.

Adrian P Banning (AP)

Oxford Heart Centre, National Institute for Health Research Biomedical Research Centre, Oxford University Hospitals, Oxford, United Kingdom. Electronic address: adrian.banning@ouh.nhs.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH